Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen

Revolution Medicines, Inc. (NASDAQ:RVMD) on Thursday reported encouraging updated results from its Phase 1/2 RMC-GI-102 open-label study of Rasonque (daraxonrasib) combined with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for metastatic pancreatic adenocarcinoma (PDAC) . The global, commercial-stage oncology company, which focuses on developing medicines for patients…

Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen

Revolution Medicines (RVMD) has released positive results from its Phase 1/2 RMC-GI-102 study on the combination of Rasonque (daraxonib) and gemcitabine/nab-paclitaxel as a potential first-line treatment for metastatic pancreatic adenocarcinoma (PDAC). The study, presented at the EORTC-NCI-AACR Symposium, showed a 76.6% 12-month overall survival rate in 61 patients who received the regimen, with a 60.7% objective response rate and a 90.2% disease control rate.

The safety profile of the combination therapy remained consistent with previous data for both Rasonque and gemcitabine/nab-paclitaxel.

Brief written by urgent.news from Benzinga's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at benzinga.com →

More in Health & Medicine

More from Friday 20 November →